International Journal of Hematology

, Volume 110, Issue 2, pp 237–243 | Cite as

Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors

  • Takashi Ishida
  • Kota Ohashi
  • Chikako Okina
  • Shiho Ohashi
  • Sosei Okina
  • Koji Miyazaki
  • Takahiro SuzukiEmail author
Original Article


Home care medicine is a platform for providing supportive care for end-stage cancers. However, for undefined reasons, patients with hematological tumors (HTs) often fail to receive opportunities for home care. We, therefore, sought to delineate the clinical differences between solid tumors (STs) and HTs and to determine whether home care is effective for patients with HTs, as well as those with STs. We retrospectively analyzed the treatments, prognosis, and places of death of patients with STs (n = 99) and HTs (n = 20) who received palliative home care in our clinic and subsequently died between May 2016 and May 2018. Patients with HTs commonly required intravenous antibiotics, platelet transfusion, and red blood cell transfusion, while patients with STs tended to more frequently require the use of opioids. Importantly, there were no significant differences between the cohorts with respect to survival time and frequency of emergent visits to patients after their referral to us. Furthermore, most patients in both groups died at home. More than 50% of patients were not admitted to hospitals during our follow-up. Collectively, while therapeutic approaches sometimes differ, this study provides clinical evidence that palliative home care can be feasible even for patients with HTs.


Home care Home visiting Palliative care Hematological tumors Transfusions at home Frail patients 



Hematological tumors


Solid tumors


Myelodysplastic syndromes


Quality of life



We thank Sachie Yamaguchi, Akiko Ryuo, Takahiro Suzuki, Jun Suzuki, Nobumasa Omura, Maki Omura, and Hironobu Hashimoto for their unselfish dedication to patient care.

Author contributions

Study conception and design, data acquisition, and data analysis and interpretation: TI, KO, CO, SO, SO, KM, and TS. Article drafting or critical revision for important intellectual content: TI, KO, KM, and TS. Final approval of the submitted version: TI, KO, CO, SO, SO, KM, and TS.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest in relation to this study.


  1. 1.
    Niscola P, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P, et al. Caring for terminal patients in haematology: the urgent need of a new research agenda. Support Care Cancer. 2015;23:5–7.CrossRefGoogle Scholar
  2. 2.
    Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR. Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med. 2011;25:630–41.CrossRefGoogle Scholar
  3. 3.
    Adachi A, Tsukada Y, Kondo S, Asakura K, Matsuki E, Kawagoe S, et al. Questionnaire survey on current status of home care and support for patients with hematological diseases. Rinsho Ketsueki. 2014;55:2262–70.Google Scholar
  4. 4.
    Higginson IJ, Koffman J. Public health and palliative care. Clin Geriatr Med. 2005;21:45–55.CrossRefGoogle Scholar
  5. 5.
    Niscola P, de Fabritiis P, Cartoni C, Romani C, Sorrentino F, Dentamaro T, et al. Home care management of patients affected by hematologic malignancies: a review. Haematol. 2006;91:1523–9.Google Scholar
  6. 6.
    Niscola P, Tendas A, Giovannini M, Cupelli L, Trawinska MM, Palombi M, et al. Transfusions at home in patients with myelodysplastic syndromes. Leuk Res. 2012;36:684–8.CrossRefGoogle Scholar
  7. 7.
    Howell DA, Roman E, Cox H, Smith AG, Patmore R, Garry AC, et al. Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy. BMC Palliat Care. 2010;9:9.CrossRefGoogle Scholar
  8. 8.
    Howell DA, Wang HI, Smith AG, Howard MR, Patmore RD, Roman E. Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to death. BMC Palliat Care. 2013;12:42.CrossRefGoogle Scholar
  9. 9.
    Joske D, McGrath P. Palliative care in haematology. Intern Med J. 2007;37:589–90.CrossRefGoogle Scholar
  10. 10.
    McGrath P. Palliative care for patients with hematological malignancies–if not, why not? J Palliat Care. 1999;15:24–30.CrossRefGoogle Scholar
  11. 11.
    van Tiel FH, Harbers MM, Kessels AG, Schouten HC. Home care versus hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia. Ann Oncol. 2005;16:195–205.CrossRefGoogle Scholar
  12. 12.
    Ringdén O, Sadeghi B, Moretti G, Finnbogadottir S, Eriksson B, Mattsson J, et al. Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Int J Hematol. 2018;107:478–85.CrossRefGoogle Scholar
  13. 13.
    LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018;132:717–26.CrossRefGoogle Scholar
  14. 14.
    Garcia D, Aguilera A, Antolin F, Arroyo JL, Lozano M, Sanroma P, et al. Home transfusion: three decades of practice at a tertiary care hospital. Transfusion. 2018;58:2309–19.CrossRefGoogle Scholar
  15. 15.
    Ohashi K, Adachi A, Hosoda T. A survey on home care needs of patients with hematological diseases. Gan To Kagaku Ryoho (in press).Google Scholar
  16. 16.
    Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315–21.CrossRefGoogle Scholar
  17. 17.
    McGrath P. Are we making progress? Not in haematology! Omega (Westport). 2002;45:331–48.CrossRefGoogle Scholar
  18. 18.
    Maddocks I, Bentley L, Sheedy J. Quality of life issues in patients dying from haematological diseases. Ann Acad Med Singapore. 1994;23:244–8.Google Scholar
  19. 19.
    Alt-Epping B, Wulf G, Nauck F. Palliative care for patients with hematological malignancies—a case series. Ann Hematol. 2011;90:613–5.CrossRefGoogle Scholar
  20. 20.
    Fadul NA, El Osta B, Dalal S, Poulter VA, Bruera E. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med. 2008;11:422–7.CrossRefGoogle Scholar
  21. 21.
    Hui D, Kim SH, Roquemore J, Dev R, Chisholm G, Bruera E. Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer. 2014;120:1743–9.CrossRefGoogle Scholar
  22. 22.
    Amano K, Morita T, Tatara R, Katayama H, Uno T, Takagi I. Association between early palliative care referrals, inpatient hospice utilization, and aggressiveness of care at the end of life. J Palliat Med. 2015;18:270–3.CrossRefGoogle Scholar
  23. 23.
    Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, et al. Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes From the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33:1446–52.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Takashi Ishida
    • 1
    • 2
    • 3
  • Kota Ohashi
    • 2
  • Chikako Okina
    • 2
    • 4
  • Shiho Ohashi
    • 2
  • Sosei Okina
    • 3
  • Koji Miyazaki
    • 1
  • Takahiro Suzuki
    • 3
    Email author
  1. 1.Department of Transfusion and Cell TransplantationKitasato University School of MedicineSagamiharaJapan
  2. 2.TOTUS Home Care ClinicKomaeJapan
  3. 3.Department of HematologyKitasato University School of MedicineSagamiharaJapan
  4. 4.Department of NephrologyKitasato University School of MedicineSagamiharaJapan

Personalised recommendations